Business Wire
28 Feb 2026, 00:00 UTC · 37w ago
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Verdict
Headline takes no side. We score IDYA +0.80 across two claims — strongly bullish.
- Expected · IDYA
+0.80strongly bullish
−1 bearish0bullish +1More positive than 88% of ticker scores this week





